1	ARNOLD & PORTER LLP			
	MAURICE A. LEITER (State Bar No. 123732)			
2	maury.leiter@aporter.com			
3	777 South Figueroa Street, 44th Floor			
3	Los Angeles, California 90017-5844			
4	Telephone: +1 213.243.4000			
•	Facsimile: +1 213.243.4199			
5				
	ARNOLD & PORTER LLP			
6	MICHAEL J. BAKER (State Bar No. 56492)			
7	michael.baker@aporter.com			
/	SHARON D. MAYO (State Bar No. 150469)			
8	sharon.mayo@aporter.com			
	Three Embarcadero Center, 10th Floor			
9	San Francisco, California 94111-4024			
10	Telephone: +1 415.471.3100			
10	Facsimile: +1 415.471.3400			
11				
11	Attorneys for Defendant Bristol-Myers Squibb Company			
12	[Additional Counsel Listed At Signature Page]			
13				
14	LIMITED STAT	ES DISTRICT COURT		
14	UNITED STATES DISTRICT COURT			
15	NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION			
	SANTKAN	CISCO DI VISION		
16	JENNIE CADDELL et al.,	No. 14-3482 RS		
17	JENNIE CRODLEE et at.,	10. 14 5402 RS		
17	Plaintiff,			
18	Tidilitiii,			
	v.	JOINT STIPULATION AND		
19	<b>*.</b>	[PROPOSED] ORDER TO STAY		
•		LITIGATION PENDING TRANSFER TO		
20	BRISTOL-MYERS SQUIBB COMPANY,	THE PLAVIX® MDL		
21	MCKESSON CORPORATION, and			
_1	DOES 1 to 100,			
22		Judge: Hon. Richard Seeborg		
	Defendants.			
23				
24				
24				
25				
26				
27				
27				
28				
_0				

1	This Joint Stipulation is made by and between Plaintiffs i		
2	Squibb Co. et al., No. CV-14-3482 RS (N.D. Cal.), and Defendan		
3	("BMS") (collectively "the Parties"), by and through the undersign		
4	reference to the following facts:		
5	1. WHEREAS, on February 12, 2013, the Judicial Pa		
6	("JPML") established a multidistrict Plavix® litigation in the Dis		
7	Judge Freda Wolfson;		
8	2. WHEREAS, on July 31, 2014, Plaintiffs filed the		
9	Court of California, San Francisco County;		
10	3. WHEREAS, on August 1, 2014, the <i>Caddell</i> actio		
11	Defendant BMS;		
12	4. WHEREAS, on August 12, 2014, Defendant BMS		
13	Plavix® MDL and anticipates that the JPML will issue a condition		
14	soon; and		
15	5. WHEREAS, the parties agree that the <i>Caddell</i> acti		
16	anticipated transfer to the Plavix® MDL in the District of New J		
17			
18	THEREFORE, IT IS HEREBY STIPULATED AND AG		
19	approval, that the Caddell action should be stayed pending its ant		
20	MDL in the District of New Jersey.		
21			
22	IT IS SO STIPULATED.		
23			
24			
25			
26			
27			
28			

This Joint Stipulation is made by and between Plaintiffs in Caddell et al. v. Bristol-Myers				
Squibb Co. et al., No. CV-14-3482 RS (N.D. Cal.), and Defendant Bristol-Myers Squibb Company				
("BMS") (collectively "the Parties"), by and through the undersigned counsel of record, with				
reference to the following facts:				
1. WHEREAS, on February 12, 2013, the Judicial Panel on Multidistrict Litigation				
("JPML") established a multidistrict Plavix® litigation in the District of New Jersey, assigned to				

- Caddell action in the Superior
- on was removed to this Court by
- S tagged this case for transfer to the onal transfer order for this case
- ion should be stayed pending its ersey.

REED, subject to the Court's ticipated transfer to the Plavix®

1		
2	Dated: August 15, 2014	Joshua C. Ezrin
3		AUDET & PARTNERS, LLP 221 Main Street, Suite 1460
4		San Francisco, CA 94105
5		Daniel C. Burke
6		PARKER WAICHMAN LLP 6 Harbor Park Drive
7		Port Washington, New York 11050
8		By:/s/ Joshua C. Ezrin
9		Joshua C. Ezrin
10		Attorney for Plaintiffs
11		
12	Dated: August 15, 2014	ARNOLD & PORTER LLP
13		Three Embarcadero Center, 10th Floor San Francisco, CA 94111
14		2421 2 1411 <b>4</b> 125
15		By: <u>/s/ Sharon D. Mayo</u> Sharon D. Mayo
16		•
17		Attorney for Defendant Bristol-Myers Squibb Company
18		
19	PURSUANT TO STIPULATION, IT IS SO ORDERED.	
20		
21		
22	Date: 8/18/14	July Seeling
23		Judge Richard Seeborg U.S. District Judge
24		
25		
26		
27		
28		